Univariate analysis | Multivariate analysis | |
---|---|---|
Freedom from local progression | ||
BED 35.7 Gy10 | 0.13 | HR 0.455 (95%CI 0.140–1.479); p = 0.19 |
GTV volume ≤ 0.4 | 0.041 | HR 3.77 (95%CI 0.945–15.061); p = 0.06 |
PTV margin | 0.59 | – |
BM site (base = midbrain) | 0.09 | Pons: HR 0.202 (95%CI 0.048–0.845); p = 0.02 M. Oblongata: HR 0.627 (95%CI 0.150–2.619); p = 0.52 |
Primary histology | 0.74 | – |
Previous WBRT | 0.85 | – |
Concurrent targeted therapy | 0.03 | HR 0.169 (95%CI 0.021–1.348); p = 0.09 |
Single- versus multifraction | 0.51 | – |
Overall survival | ||
BED 35.7 Gy10 | 0.06 | HR 0.887 (95%CI 0.534–1.473); p = 0.64 |
GTV volume ≤ 0.4 | 0.45 | – |
PTV margin | 0.17 | – |
Primary histology | 0.17 | |
BM site | 0.16 | – |
Previous WBRT | 0.01 | HR 1.59 (95%CI 0.827–3.080); p = 0.16 |
Concurrent targeted therapy | 0.01 | HR 0.466 (95%CI 0.270–0.804); p = 0.006 |
Single-versus multifraction | 0.03 | HR 1.61 (95%CI 0.972–2.696); p = 0.06 |
Cancer-specific survival | ||
BED 35.7 Gy10 | 0.26 | – |
GTV volume ≤ 0.4 | 0.33 | – |
PTV margin | 0.23 | – |
BM site (base = midbrain) | 0.06 | Pons: HR 0.587 (95%CI 0.338–1.019); p = 0.06 M. oblongata: HR 1.026 (95%CI 0.505–2.082); p = 0.94 |
Primary histology | 0.23 | |
Previous WBRT | 0.03 | HR 2.055 (95%CI 1.023–4.128); p = 0.04 |
Concurrent targeted therapy | 0.03 | HR 0.573 (95%CI 0.331–0.992); p = 0.04 |
Single- versus multifraction | 0.11 | – |
Neurological Death | ||
BED 35.7 Gy10 | 0.75 | – |
GTV volume ≤ 0.4 | 0.75 | – |
PTV margin | 0.54 | – |
Primary histology | 0.23 | |
BM site (base = midbrain) | 0.15 | Pons: HR 0.431 (95%CI 0.179–1.037); p = 0.06 M. Oblongata: HR 0.631 (95%CI 0.172–2.308); p = 0.48 |
Previous WBRT | 0.00 | HR 3.381 (95%CI 1.287–8.879); p = 0.01 |
Concurrent targeted therapy | 0.13 | 0.530 (95%CI 0.197–1.427); p = 0.21 |
Single- versus multifraction | 0.74 | – |